References of "Dresse, Marie-Françoise"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailNewborn screening for sickle cell disease : 13 years at the CHR "La Citadelle", Liège
Sepulchre, Edith; Ketelslegers, Olivier; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016, March), 18(1), 107

Detailed reference viewed: 12 (1 ULg)
Full Text
See detailContraception hormonale chez l'adolescente avec thrombophilie biologique
Minon, Jean-Marc; Vasbien, Myriam; DRESSE, Marie-Françoise ULg et al

in Belgian Journal of Paediatrics (2016), 18(2), 173-176

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the ... [more ▼]

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the contraceptive patch and vaginal ring. Hence, the adolescents with a know biological thrombophilia should not take htis type of hormonal conraception. However, some of these thrombophilia should not preclude use of estrogen containing contraception. Actually, if thrombophilia testing can be justified in asymptomtic patient at high risk, it is sometimes performed as screening in adolescent before estrogen-containnig contraception use ( non recommended). In these situations and considering the venous thrombosis as a multicausal disease, the choice of contraceptive methods is argued on the base of family history and other personnal risk factors of venous thrombosis. [less ▲]

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailPurpura thrombocytopénique idiopathique...idiopathique, vraiment?
LONGTON, Julie ULg; DRESSE, Marie-Françoise ULg; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016), 18(1), 112

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailTumeurs rhabdoïdes néonatales : à propos de deux cas.
Carichon, T; FORGET, Patricia ULg; Piette, Caroline ULg et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailPosterior Reversible Encephalopathy Syndrome in Pediatric Leukemia
Carichon, Tifenn ULg; Piette, Caroline ULg; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 48

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailSplénomégalie palustre hyperimmune et drépanocytose. A propos d'un cas
Lefevre, Annabelle; Hoyoux, Marie; DRESSE, Marie-Françoise ULg

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailL'impact d'un programme régulier d'Erythrocytaphérèse sur les complications de la drépanocytose
DRESSE, Marie-Françoise ULg; Hoyoux, Marie; Ketelslegers, Olivier et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 82

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailDescription and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients
Meyran, Deborah; Petit, Arnaud; Guilhot, Joelle et al

Poster (2015)

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency ... [more ▼]

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency of accelerated phase (AP) or blast crisis (BC) is remarkably reduced, estimated to 1% to 1.5% per year in adults compared with more than 20% per year in the pre-TKI era. But no data are available among children. Purpose: We described the characteristics, the treatment and the outcome of 21 children with CML, who evolved in accelerated phase and/or blast crisis under TKI. Results: From 2001 to april 2015, 415 European patients were enrolled in the CML pediatric database. Twenty-one patients (5.1%), in chronic phase (CP) treated by TKI, presented AP or BC. The median age of AP /BC cohort was 13.2 years (range: 4.5-16.9 years) with a sex ratio M/F at 2. At CML diagnosis, 15 patients (71%) had high risk Sokal Score with a median score of 1,4 (range: 0,16-2,4). All patients harbored t(9;22)(q34;q11) but one had a complex translocation t(1;9;22)(q12;q34;q11) and another one presented additional inv(3)(q21q26). Imatinib was the first line TKI for all patients. Before AP or BC, only five patients (24%) obtained a complete cytogenetic response (CCyR) and three achieved MMR. For incomplete molecular response or progression to accelerated phase, 8 patients (38%) were switched to dasatinib. Median duration of TKI before AP or BC was 11 months (range: 3 months-56.5 months). Six patients evolved to AP with a median interval of 8.7 months (range: 1 months-24 months), leading to blast crisis for 4 patients with a median time of 3.5 months (range: 0.3-5.4 months). Among the 2 patients remaining in AP, imatinib was increased for one and the other was switched for dasatinib, all before hematopoietic stem cells transplantation (HSCT). One patient died of post-transplant complication and the other one is still alive in complete molecular response without TKI. Nineteen patients presented BC, including 4 after AP. Thirteen patients (62%) presented ALL, five (24%) AML and one a bi phenotypic leukemia. Central nervous system (CNS) was involved for two patients with ALL, one isolated, one combined. At AP or BC, nine patients (43%) presented new additional cytogenetic abnormalities. Eighteen patients with BC were treated according to AML or ALL protocols, combined with second generation TKI for twelve patients. Only one patient underwent preparative regimen, without intensive chemotherapy before HSCT. Ten patients reached complete remission. Four patients died before HSCT, by progressive disease for 2 and by fatal infection for 2. Overall, 15 patients in BC were transplanted. Before HSCT, median molecular response was 0.2% (range: 0-29%) and only four patients had a complete molecular response. After transplant, seven patients received second generation TKI. Four patients died, including three related to transplant toxicity. Thirteen patients were alive, but one with ALL BC relapsed 26 months post-transplant and was waiting for second HSCT. With a median follow-up of 4.4 years, 4-year overall survival was 59% (66% for ALL BC versus 40% for AML BC). Conclusion: Incidence of AP/BC after imatinib for CP CML is at 5%, in the CML pediatric database. Despite second generation TKI, combined with HSCT, outcome remains poor. Post-transplant indication of TKI is heterogenic. Recommendations would be useful for practice. [less ▲]

Detailed reference viewed: 29 (2 ULg)
Full Text
Peer Reviewed
See detailSchizencephaly associated with a severe prothrombotic syndrome caused by antithombin III deficiency
Daron, Aurore; DRESSE, Marie-Françoise ULg; Hoyoux, Claire ULg et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 109

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailDécrochage de la courbe de périmètre crânien et si l’origine n'était pas neurologique
LONGTON, Julie ULg; DRESSE, Marie-Françoise ULg; Hoyoux, Marie et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailUNE TUMEUR RARE DE LA FACE CHEZ UN NOURRISSON DE 6 MOIS
Fontaine, C; DEMEZ, Pierre ULg; FORGET, Patricia ULg et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailLE CANCER DU TRES JEUNE ENFANT : EPIDEMIOLOGIE LIEGEOISE
Fontaine, C; RIGO, Vincent ULg; FORGET, Patricia ULg et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 47

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailUTILISATION D'UNE FISTULE ARTERIO-VEINEUSE CHEZ DES PATIENTS DREPANOCYTAIRES SOUS ERYTHROCYTAPHERESE
Hoyoux, Marie; DRESSE, Marie-Françoise ULg; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 49

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailSurvival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment
Lê, Phu Quoc; Gulbis, Béatrice; Dedeken, Laurence et al

in Pediatric Blood & Cancer (2015), 62

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry ... [more ▼]

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry created in 2008 included patients of eight centers. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from neonatal screening or from diagnosis (first contact) until last follow-up or death. Data included diagnosis, demography, and outcome data. Results. We collected data from 469 patients over a 5,110 patient years (PY) follow-up period. The global mortality rate was low (0.25/100 PY), although 13 patients died (2.8%) and was similar between children, adolescents (10–18 years), and young adults (P¼0.76). Out of the cohort, 185 patients received hydroxyurea at last follow-up (median duration of treatment: 10.3 years), 90 underwent hematopoietic stem cell transplantation (HSCT), 24 were chronically transfused, and 170 had never had any DMT. Hydroxyurea showed significant benefit on patients outcome as reflected by a lower mortality rate compared to transplanted individuals or people without DMT (0.14, 0.36, and 0.38 per 100 PY, respectively) and by higher Kaplan–Meier estimates of 15 year survival (99.4%) compared to HSCT (93.8%; P¼0.01) or no DMT groups (95.4%; P¼0.04). Conclusion. SCD mortality in Belgium is low with no increase observed in young adults. Patients treated with hydroxyurea demonstrate a significant benefit in survival when compared to those withoutDMTor transplanted. [less ▲]

Detailed reference viewed: 40 (3 ULg)
Full Text
Peer Reviewed
See detailCOMMENT J’EXPLORE ET TRAITE UNE THROMBOSE VEINEUSE RÉNALE NÉONATALE : à propos d’un cas
Tribolet, S.; DRESSE, Marie-Françoise ULg; Lombet, J. et al

in Revue Médicale de Liège (2014), 69(4), 169-174

Neonatal renal vein thrombosis is a rare condition. The present case is rather unfrequent and particularly educative since it shows the complete diagnostic triad including hematuria, flank mass and ... [more ▼]

Neonatal renal vein thrombosis is a rare condition. The present case is rather unfrequent and particularly educative since it shows the complete diagnostic triad including hematuria, flank mass and thrombocytopenia. The diagnosis relies on the demonstration, by Doppler ultrasound, of an obstructed renal venous bed. The investigation is completed by a platelet count and the determination of the prothrombin time, of the activated partial thromboplastin time as well as of the concentration of fibrinogen. The screening also includes the search for a possible etiology, such as a deficiency in coagulation proteins, the presence of antiphospholipid antibodies or of a genetic mutation of one of the coagulation factors. Since there exist no evidence based guidelines for the management of the disease, we will discuss the diagnosis and treatment in relation with the published literature. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailMinimal residual disease quantification by PCR in childhood acute lymphoblastic leukemia
Van der Straeten, J.; De Moerloose, B.; DRESSE, Marie-Françoise ULg et al

in Belgian Journal of Hematology (2014), 5

ln Belgium approximately 70 children are diagnosed with acute Iymphoblastic leukaemia annually. For these children, the monitoring of minimal residual disease has an important prognostic value. The level ... [more ▼]

ln Belgium approximately 70 children are diagnosed with acute Iymphoblastic leukaemia annually. For these children, the monitoring of minimal residual disease has an important prognostic value. The level of minimal residual disease during the first three months of therapy is used to recognise subgroups that differ substantially in outcome. Two techniques are used for minimal residual disease monitoring: the Genescan method and the allele specifie oligonucleotide polymerase chain reaction. The Genescan method is a less sensitive method (10-3) but is fast and less expensive. The allele specifie oligonucleotide polymerase chain reaction requires more time and budget but has a sensitivity of 10-4-10-5• Both techniques have proven their value in minimal residual disease monitoring in childhood acute Iymphoblastic leukaemia. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailManaging children with chronic myeloid leukaemia (CML) Recommendations for the management of CML in children and young people up to the age of 18 years
de la Fuente, Josu; Baruchel, André; Biondi, Andrea et al

in British Journal of Haematology (2014), 167

Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that ... [more ▼]

Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults. Significant advances in targeted therapy with the development and use in children of tyrosine kinase inhibitors and the ability to monitor and understand the prognostic significance of minimal residual disease by standardized molecular techniques has shifted the management of this condition from bone marrow transplantation as the main therapeutic modality to individualized treatment for each patient based on achieving specific milestones. The physiological changes occurring during childhood, particularly those affecting growth and development and the long-term use of treatment, pose specific challenges in this age group, which we are only beginning to understand. [less ▲]

Detailed reference viewed: 52 (2 ULg)
Full Text
Peer Reviewed
See detailOsteopetrosis mimicking juvenile myelomonocytic leukemia.
Hoyoux, Claire ULg; DRESSE, Marie-Françoise ULg; Forget, Patricia et al

in Pediatrics international : official journal of the Japan Pediatric Society (2014), 56(5), 779-82

A 5-month-old boy developed splenomegaly, anemia, thrombocytopenia with elevated white cells, monocytosis and immature granulocytes in the peripheral blood. Bone marrow showed dysplasia without blastosis ... [more ▼]

A 5-month-old boy developed splenomegaly, anemia, thrombocytopenia with elevated white cells, monocytosis and immature granulocytes in the peripheral blood. Bone marrow showed dysplasia without blastosis. Increased colony-forming unit-granulocyte-macrophage was found in the peripheral blood, mimicking granulocyte-macrophage colony-stimulating factor hypersensitivity. These findings fulfilled the diagnosis criteria for juvenile myelomonocytic leukemia (JMML), but no mutations in the CBL, NRAS, KRAS, or PTPN11 genes were detected. In addition to these findings severe hypogammaglobulinemia and elevated alkaline phosphatase were present. Bone X-ray showed dense and radiopaque bones with a bone-in-bone appearance characteristic of infantile malignant osteopetrosis (IMO). Genetic mutation in T-cell, immune regulator 1 (TCIRG1) was identified, confirming the diagnosis of IMO. Careful differential diagnosis including osteopetrosis, is therefore recommended in patients with clinical features and hematologic findings consistent with JMML. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailPILOT PROJECT IN CHR-LIEGE: INVITING SIBLINGS OF CHILDREN WITH CANCER TO A CREATIVE AND EXPRESSIVE WEEK-END WITH PSYCHOLOGISTS AND ONCOLOGIST
Forget, Patricia; Badot, Isabelle; Missotten, Pierre ULg et al

Poster (2013, September 27)

The siblings week end with the psycho-medical team was highly successful It opens another way to improve the care of the siblings Questionnary forms should be developped in the future to evaluate the real ... [more ▼]

The siblings week end with the psycho-medical team was highly successful It opens another way to improve the care of the siblings Questionnary forms should be developped in the future to evaluate the real psychological impact [less ▲]

Detailed reference viewed: 56 (4 ULg)
Full Text
Peer Reviewed
See detailLow Sickle Cell Disease Mortality In Belgium and Benefit From Hydroxyurea Therapy
Lê, Phu-Quoc; Dedeken, Laurence; Gulbis, Beatrice et al

Poster (2013)

In Western countries, mortality among patients with sickle cell disease (SCD) has decreased in the last decades by means of neonatal screening (NS), infectious prophylaxis and care improvements. The major ... [more ▼]

In Western countries, mortality among patients with sickle cell disease (SCD) has decreased in the last decades by means of neonatal screening (NS), infectious prophylaxis and care improvements. The major causes of death in children include acute chest syndrome, sepsis, splenic sequestration, stroke, aplastic crisis while in adults end-stage organ failure contributes also to premature death. Hydroxyurea (HU) and stem cell transplantation (SCT) are used in Belgium for more than 20 years but their possible influences on survival have not been yet analyzed. The Belgian SCD Registry was created in 2008 including patients of 8 centres. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from NS or from diagnosis (first contact) until last follow up (FU) visit, SCT or death. Data included diagnosis, demography and outcome data. After SCT, only vital status and cause of death were recorded. Up to date, data from 470 pts are recorded (224 males), 412 are HbSS, 14 HbSβ0, 7 HbSβ+ and 37 HbSC. The median age at diagnosis and at last FU was respectively 0.7 year (y) and 9.9 y. The FU for the whole cohort was 3810 patient-years (PY) and with 136 patients aged over 18y, their FU during adulthood accounted for 520 PY. Thirteen patients died (2.8%). The mortality per 100-PY was 0.34 and the median age at death was 14.5 y (range, 1.5-23.7 y). All deaths occurred in HbSS patients, 5 after SCT and 8 due to an acute event. Complete data set is missing for 3 of the 8 patients. For the 5 well documented SCD related deaths, causes were: hemorrhagic stroke (2), sepsis due to S. pneumoniae (1), aplastic crisis (1) and infection during stay in homeland (1). At last FU, 91 patients were transplanted, 182 were on HU, 7 on HU + chronic transfusion (CT), 19 on CT (4 after HU treatment). The remaining 171 patients never had disease modifying therapy (DMT). Compared with the latter, mortality rate for those on HU was significantly reduced (0.1 vs 0.5/100-PY) while patients on HU have longer FU and are older at last FU (Table 1). Among 91 patients transplanted at a median age 6.9 y, 5 died: 3 from acute transplant related toxicity, 1 from secondary acute myeloblastic leukemia after cGVHD, and 1 is unexplained more than 7 years post SCT. The data issued from the most recent NS cohorts report a low death rate during childhood ranging from 0.13 to 0.52. Even if our Belgian cohort is not exclusively issued from neonatal diagnosis, the observed death rate is low (0.34/100-PY). Several methodological biases are present in this partially retrospective study (incomplete or unavailable data, lost of FU, no information if death occurred before the first contact in a center, …). Nevertheless our low mortality is not underestimated since 1) most patients were followed since infancy and during a long period (3810 PY); 2) the FU during adulthood (period of increased mortality) accounted for 520 PY; 3) our cohort represents a very large part of the Belgian SCD population since a national inquiry performed in 2007 estimated the whole SCD population to 500. The effect of HU on mortality has been reported in adults and more recently in children. Despite longer FU and older age at last FU, our data confirms those previously results. With only one case, death by infection is rare while SCT complications contributed to about 40 % of deaths. Even if SCT is the only curative option for SCD, it encompasses a risk of mortality. As life expectancy of SCD patients has been extended which is confirmed by our results (especially for patients on HU), SCT should be reserved for clinically severe cases. Population-based prospective studies evaluating the survival in transplanted and non transplanted patients are needed. [less ▲]

Detailed reference viewed: 22 (1 ULg)